Vontobel Holding Ltd. Has $10.48 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Vontobel Holding Ltd. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 14.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,309 shares of the medical research company’s stock after selling 9,261 shares during the quarter. Vontobel Holding Ltd.’s holdings in IQVIA were worth $10,476,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in IQVIA during the 3rd quarter worth $27,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the period. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter worth about $33,000. Assetmark Inc. grew its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, Concord Wealth Partners acquired a new stake in shares of IQVIA in the 3rd quarter valued at about $57,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $193.65 on Friday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company’s 50 day moving average price is $200.59 and its two-hundred day moving average price is $218.51. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $35.15 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research reports. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Leerink Partners restated an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. JPMorgan Chase & Co. reduced their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Finally, UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $251.67.

Insider Buying and Selling

In related news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.